突发新闻：伊维菌素 + 甲苯咪唑最大规模人类癌症研究现已通过同行评审并在主要癌症期刊上发表

84.4% 的服用伊维菌素 + 甲苯咪唑 6 个月的癌症患者报告称癌症消失、肿瘤消退或癌症稳定。

我们的研究《伊维菌素和甲苯咪唑在癌症患者中的真实世界临床结局：来自前瞻性观察队列的结果》现已通过同行评审并发表在《Anticancer Research》上——这是国际抗癌研究所（IIAR）于 1995 年创立的主要国际肿瘤学期刊。

这些结果代表了肿瘤学中再利用抗寄生虫疗法有史以来最令人信服的临床信号之一。

一项多样化的癌症患者群体（n=197）通过美国远程医疗平台开具了复合伊维菌素–甲苯咪唑，每粒胶囊含有 25 mg 伊维菌素和 250 mg 甲苯咪唑。

参与者使用标准化数字调查表进行了约六个月的随访，评估癌症结局、药物依从性和耐受性。

在治疗开始后约六个月，我们观察到 84.4% 的临床获益率 (CBR)——这意味着超过五分之四的患者报告称：无疾病证据 (32.8%)肿瘤消退 (15.6%)或癌症稳定 (36.1%)

重要的是，依从性非常高，86.9% 的患者完成了初始处方，66.4% 的患者在六个月时仍继续治疗。

副作用主要为轻微且可控，25.4% 的患者报告（主要是胃肠道），其中 93.6% 的患者在轻微剂量调整后继续治疗。

这项开创性的同行评审出版物得益于 The Wellness Company、McCullough Foundation 和总统癌症小组主席之间的独特合作——将真实世界临床数据、前线医疗经验和流行病学专业知识相结合，评估具有重大转化潜力的廉价再利用疗法。

凭借这些异常有前景的结果，现在需要进行双盲、安慰剂对照临床试验。

与此同时，许多癌症患者正在行使他们的尝试权。

BREAKING: Largest Human Cancer Study of Ivermectin + Mebendazole Is Now PEER-REVIEWED and PUBLISHED in a MAJOR Cancer Journal

84.4% of cancer patients taking ivermectin + mebendazole for 6 months declared either CANCER DISAPPEARANCE, TUMOR REGRESSION, or CANCER STABILIZATION.

Our study, “Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort,” is now peer-reviewed and published in Anticancer Research—a major international oncology journal of the International Institute of Anticancer Research (IIAR), established in 1995.

The results represent one of the most compelling clinical signals ever documented for repurposed anti-parasitic therapies in oncology.

A diverse population of cancer patients (n=197) was prescribed compounded ivermectin–mebendazole through a U.S. telemedicine platform, with each capsule containing 25 mg ivermectin and 250 mg mebendazole.

Participants were followed for approximately six months using standardized digital surveys assessing cancer outcomes, medication adherence, and tolerability.

At approximately six months post-treatment initiation, we observed an 84.4% Clinical Benefit Ratio (CBR)—meaning more than four out of five patients reported either:No evidence of disease (32.8%)Tumor regression (15.6%)or Cancer stabilization (36.1%)

Importantly, adherence was remarkably high, with 86.9% completing the initial prescription and 66.4% remaining on therapy at six months.

Side effects were predominantly mild and manageable, reported in 25.4% of patients (primarily gastrointestinal), with 93.6% of those experiencing side effects continuing treatment after minor dosing adjustments.

This groundbreaking peer-reviewed publication was made possible through a unique collaboration between The Wellness Company, the McCullough Foundation, and the Chairman of the President’s Cancer Panel—uniting real-world clinical data, frontline medical experience, and epidemiologic expertise to evaluate inexpensive, repurposed therapies with major translational potential.

With these extraordinarily promising results, double-blind, placebo-controlled clinical trials are now required.

In the meantime, many cancer patients are exercising their right to try.